Effects of Atenolol or Losartan on Fibrinolysis and von Willebrand Factor in Hypertensive Patients With Left Ventricular Hypertrophy

Kurt Boman(Umeå University), Björn Dahlöf(Thermo Fisher Scientific (Sweden)), Mona Olofsson(Skellefteå Hospital), Jenny Hernestål Boman(Skellefteå Hospital), Jonas Andersson(Skellefteå Hospital)

Clinical and Applied Thrombosis/Hemostasis

October 13, 2009

10.1177/1076029609349501

Cited by 7

Related Papers

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

|The Lancet|1998|5.8k

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

|The Lancet|2005|2.9k

SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe

|European Heart Journal|2021|1.7k

Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis

|New England Journal of Medicine|2008|1.6k

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|1.6k